Cencora, Inc. (ABC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1150309,
    "name": "Cencora, Inc.",
    "stock_name": "Cencora, Inc.",
    "full_name": "Cencora, Inc.",
    "name_url": "stocks-analysis/cencora-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "337.63",
    "chg": 2.32,
    "chgp": "0.69%",
    "dir": 1,
    "prev_price": "335.31",
    "mcapval": "82,361.60",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 3270,
    "indexname": "S&P 500",
    "isin": "US03073E1055",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "854.2 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cencora-inc-1150309-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Cencora, Inc. Hits New 52-Week High at $350.46, Up 45.46%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cencora-inc-hits-new-52-week-high-at-35046-up-4546-3661923",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CencoraInc_priceRelatedfactors_3661923.png",
        "date": "2025-10-31 16:09:08",
        "description": "Cencora, Inc. has achieved a new 52-week high, reflecting strong performance with a significant increase over the past year. The company, with a market capitalization of USD 82,362 million, features a high P/E ratio and a notable dividend yield, alongside impressive return on equity and a considerable debt-to-equity ratio."
      },
      {
        "title": "Cencora, Inc. Hits New 52-Week High at $334.27, Showcasing Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cencora-inc-hits-new-52-week-high-at-33427-showcasing-strong-growth-3649244",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CencoraInc_priceRelatedfactors_3649244.png",
        "date": "2025-10-27 16:49:40",
        "description": "Cencora, Inc. has achieved a new 52-week high of USD 334.27, reflecting a strong performance with a 41.84% increase over the past year. The company, with a market cap of USD 82,362 million, features a P/E ratio of 44.00 and a notable dividend yield of 27.26%."
      },
      {
        "title": "Cencora, Inc. Hits New 52-Week High at USD 331.73",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cencora-inc-hits-new-52-week-high-at-usd-33173-3641254",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CencoraInc_priceRelatedfactors_3641254.png",
        "date": "2025-10-23 17:04:49",
        "description": "Cencora, Inc. achieved a new 52-week high of USD 331.73 on October 22, 2025, reflecting a significant performance increase over the past year. With a market capitalization of USD 82,362 million, the company shows strong financial metrics, including a high return on equity and substantial dividend yield."
      },
      {
        "title": "Is Cencora, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cencora-inc-overvalued-or-undervalued-3637695",
        "imagepath": "",
        "date": "2025-10-21 12:07:16",
        "description": "As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is at a risky valuation with a P/E of 57.25.\n\nCencora's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%. This strong performance reinforces the notion that the stock is fairly valued in the current market environment...."
      },
      {
        "title": "Cencora, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cencora-inc-sees-valuation-grade-change-from-very-expensive-to-fair-3640472",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CencoraInc_valuationdot_3640472.png",
        "date": "2025-10-20 15:27:17",
        "description": "Cencora, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 44 and a price-to-book value of 78.87. The company features a high dividend yield of 40.88% and impressive returns on capital and equity. Its year-to-date performance significantly surpasses that of the S&P 500."
      },
      {
        "title": "Is Cencora, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cencora-inc-overvalued-or-undervalued-3634563",
        "imagepath": "",
        "date": "2025-10-20 12:24:39",
        "description": "As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is rated as risky with a P/E of 57.25.\n\nCencora's strong performance is further highlighted by its impressive return metrics, achieving a 44.51% return year-to-date compared to the S&P 500's 13.30%, and a remarkable 226.26% return over the past five years, slightly underperforming the S&P 500's 227.77% in the same period. Overall, these factors suggest that Cencora is fairly valued in the current market context...."
      },
      {
        "title": "Is Cencora, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cencora-inc-overvalued-or-undervalued-3632103",
        "imagepath": "",
        "date": "2025-10-19 12:02:14",
        "description": "As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a P/E of 73.71 and an EV to EBITDA of 45.38, while McKesson Corp. shows a P/E of 57.25 and an EV to EBITDA of 37.15, indicating that Cencora is positioned more favorably relative to these peers.\n\nCencora's stock has significantly outperformed the S&P 500, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%, reinforcing the notion that the stock is fairly valued given its strong performance metrics...."
      },
      {
        "title": "Cencora, Inc. Hits New 52-Week High at $320.37",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cencora-inc-hits-new-52-week-high-at-32037-3626599",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CencoraInc_priceRelatedfactors_3626599.png",
        "date": "2025-10-16 18:13:57",
        "description": "Cencora, Inc. achieved a new 52-week high of USD 320.37 on October 15, 2025, reflecting a strong performance with a 36.25% increase over the past year. The company has a market capitalization of USD 82,362 million, a P/E ratio of 44.00, and a return on equity of 103.76%."
      },
      {
        "title": "Cencora, Inc. Hits New 52-Week High at USD 319.87",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cencora-inc-hits-new-52-week-high-at-usd-31987-3620102",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CencoraInc_priceRelatedfactors_3620102.png",
        "date": "2025-10-14 18:44:48",
        "description": "Cencora, Inc. has reached a new 52-week high, reflecting strong performance with a significant increase over the past year. The company, with a market capitalization of USD 82,362 million, features a high P/E ratio and a notable dividend yield, alongside impressive return on equity and a considerable debt-to-equity ratio."
      }
    ],
    "total": 23,
    "sid": "1150309",
    "stock_news_url": "https://www.marketsmojo.com/news/cencora-inc-1150309"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Cencora, Inc. Hits New 52-Week High at $350.46, Up 45.46%

2025-10-31 16:09:08

Cencora, Inc. has achieved a new 52-week high, reflecting strong performance with a significant increase over the past year. The company, with a market capitalization of USD 82,362 million, features a high P/E ratio and a notable dividend yield, alongside impressive return on equity and a considerable debt-to-equity ratio.

Cencora, Inc. Hits New 52-Week High at $334.27, Showcasing Strong Growth

2025-10-27 16:49:40

Cencora, Inc. has achieved a new 52-week high of USD 334.27, reflecting a strong performance with a 41.84% increase over the past year. The company, with a market cap of USD 82,362 million, features a P/E ratio of 44.00 and a notable dividend yield of 27.26%.

Cencora, Inc. Hits New 52-Week High at USD 331.73

2025-10-23 17:04:49

Cencora, Inc. achieved a new 52-week high of USD 331.73 on October 22, 2025, reflecting a significant performance increase over the past year. With a market capitalization of USD 82,362 million, the company shows strong financial metrics, including a high return on equity and substantial dividend yield.

Is Cencora, Inc. overvalued or undervalued?

2025-10-21 12:07:16

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is at a risky valuation with a P/E of 57.25. Cencora's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%. This strong performance reinforces the notion that the stock is fairly valued in the current market environment....

Cencora, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-10-20 15:27:17

Cencora, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 44 and a price-to-book value of 78.87. The company features a high dividend yield of 40.88% and impressive returns on capital and equity. Its year-to-date performance significantly surpasses that of the S&P 500.

Is Cencora, Inc. overvalued or undervalued?

2025-10-20 12:24:39

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is rated as risky with a P/E of 57.25. Cencora's strong performance is further highlighted by its impressive return metrics, achieving a 44.51% return year-to-date compared to the S&P 500's 13.30%, and a remarkable 226.26% return over the past five years, slightly underperforming the S&P 500's 227.77% in the same period. Overall, these factors suggest that Cencora is fairly valued in the current market context....

Is Cencora, Inc. overvalued or undervalued?

2025-10-19 12:02:14

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a P/E of 73.71 and an EV to EBITDA of 45.38, while McKesson Corp. shows a P/E of 57.25 and an EV to EBITDA of 37.15, indicating that Cencora is positioned more favorably relative to these peers. Cencora's stock has significantly outperformed the S&P 500, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%, reinforcing the notion that the stock is fairly valued given its strong performance metrics....

Cencora, Inc. Hits New 52-Week High at $320.37

2025-10-16 18:13:57

Cencora, Inc. achieved a new 52-week high of USD 320.37 on October 15, 2025, reflecting a strong performance with a 36.25% increase over the past year. The company has a market capitalization of USD 82,362 million, a P/E ratio of 44.00, and a return on equity of 103.76%.

Cencora, Inc. Hits New 52-Week High at USD 319.87

2025-10-14 18:44:48

Cencora, Inc. has reached a new 52-week high, reflecting strong performance with a significant increase over the past year. The company, with a market capitalization of USD 82,362 million, features a high P/E ratio and a notable dividend yield, alongside impressive return on equity and a considerable debt-to-equity ratio.

View All News